-
Daraxonrasib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Daraxonrasib 2765081-21-6 Jun, 2028 Jan.24, 2042 estimated PV Completion – Mar, 2028 [Indication]
- For the treatment of patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
-
Dabrafenib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Dabrafenib 1195765-45-7 Q2, 2027 Jul.20, 2030 estimated PV Completion – Q1, 2027 [Product]
Provide the API as well as Trametinib（CAS No.:871700-17-3）.
[Indication]
1. For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.
2. In combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation.
3. In combination with trametinib for the adjuvant treatment of patients with Stage III melanoma with BRAF V600E or V600K mutation who have undergone complete resection.
4. In combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
5. In combination with trametinib for the treatment of patients with locally recurrent or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation.
-
Darolutamide
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Darolutamide 1297538-32-9 ✓ Mar.25, 2033 Commercial Prodction [Indication]
Non-metastatic Castration-resistant Prostate Cancer (nmCRPC): In combination with androgen deprivation therapy (ADT) for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).
-
Deucravacitinib
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Deucravacitinib 1609392-27-9 041093 Nov.07, 2033 PV Completion [Indication]
1. It is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
2. For the treatment of adults with active psoriatic arthritis.
-
Dabigatran Etexilate Mesylate
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Dabigatran Etexilate Mesylate 872728-81-9 ✓ Dec.28, 2021 Commercial Production [Indication]
1. To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
2. For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE.
3. For the prevention of venous thromboembolism (VTE) in patients who have undergone hip or knee replacement surgery.
-
Daclatasvir Dihydrochloride
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Daclatasvir Dihydrochloride 1009119-65-6 ✓ Jul.24, 2029 [Indication]
For the treatment of chronic hepatitis C virus (HCV) infection in adults, in combination with other direct-acting antiviral agents.
-
Doxycycline Monohydrate
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Doxycycline Monohydrate 564-25-0 18959 Commercial Production [Indication]
Doxycycline is a broad-spectrum tetracycline antibiotic indicated for the treatment of a wide range of bacterial infections caused by susceptible organisms, as well as for the prophylaxis of malaria.
1. Rickettsial infections (Rocky Mountain spotted fever, typhus fever, Q fever, etc.)
2. Mycoplasma pneumoniae infections
3. Chlamydial infections (lymphogranuloma venereum, psittacosis, trachoma, nongonococcal urethritis, etc.)
4. Gram-negative bacterial infections (plague, cholera, tularemia, brucellosis, etc.)
5. Gram-positive bacterial infections (Streptococcus pneumoniae infections, post-exposure prophylaxis of anthrax, etc.)
6. Alternative therapy in penicillin-allergic patients (syphilis, gonorrhea, etc.)
7. Adjunctive therapy for severe acne
8. Malaria prophylaxis (short-term travelers to chloroquine-resistant areas)
-
Doxycycline Hyclate
API’s Name CAS No. US DMF Patent Expiry Date (US) Current Status Doxycycline Hyclate 10592-13-9 13771 Commercial Production [Indication]
Doxycycline is a broad-spectrum tetracycline antibiotic indicated for the treatment of a wide range of bacterial infections caused by susceptible organisms, as well as for the prophylaxis of malaria.
1. Rickettsial infections (Rocky Mountain spotted fever, typhus fever, Q fever, etc.)
2. Mycoplasma pneumoniae infections
3. Chlamydial infections (lymphogranuloma venereum, psittacosis, trachoma, nongonococcal urethritis, etc.)
4. Gram-negative bacterial infections (plague, cholera, tularemia, brucellosis, etc.)
5. Gram-positive bacterial infections (Streptococcus pneumoniae infections, post-exposure prophylaxis of anthrax, etc.)
6. Alternative therapy in penicillin-allergic patients (syphilis, gonorrhea, etc.)
7. Adjunctive therapy for severe acne
8. Malaria prophylaxis (short-term travelers to chloroquine-resistant areas)